慢性睡眠干扰 z-bo 2020-11-16 360

　　Objective: To study the antidepressant effect of ginsenoside hydrolysate DS-1226 on mice with chronic sleep disturbance, and to provide scientific basis for the development of antidepressant drugs.

　　Methods: 72 male ICR mice were divided into blank control group, model group, positive control group (paroxetine hydrochloride, 10 mg/kg), DS-1226 low-dose group (20 mg/kg), and middle-dose group (40 mg/kg). mg/kg), high-dose group (80 mg/kg). Except for the blank group, mice in the other groups were first adapted to the rollers for 3 days, and then continuously disturbed for 14 days. The antidepressant effect of DS-1226 was evaluated by using experimental methods such as weight monitoring, autonomous activity experiment, tail suspension experiment, and forced swimming experiment.

　　Result: After 14 consecutive days of sleep disturbance, compared with the blank control group, the weight of the model group decreased significantly, and the time of tail suspension and forced swimming immobility increased significantly. Compared with the model group, the DS-1226 medium-dose group significantly reversed the weight loss caused by sleep disturbance, while the other administration groups failed to significantly reverse the weight loss caused by sleep disturbance; the positive drug group had extremely immobile tail suspension time Significantly reduced, the time of forced swimming immobility has a decreasing trend; DS-1226 medium-dose tail suspension time is significantly reduced, and the forced swimming immobility time has a significant reduction trend; DS-1226 high-dose group has both tail suspension and forced swimming immobility time Significantly reduced.

　　Conclusion: DS-1226 has the effect of improving depression-like behavior in mice with chronic sleep disturbance.